Web Analytics

3 Latest Announced Rounds

  • $10,000,000
    Seed

    1 Investors

    Data Infrastructure and Analytics
    Aug 22nd, 2025
  • $4,873,008
    Seed

    4 Investors

    Residential Building Construction
    Aug 22nd, 2025
  • $20,000,000
    Series A

    2 Investors

    Medical Equipment Manufacturing
    Aug 22nd, 2025
$901.54M Raised in 52 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Glycomine Inc.

start up
United States - San Carlos, California
  • 17/04/2025
  • Series C
  • $115,000,000

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.


Related People

Steven AxonFounder

Steven Axon United States - Cohasset, Massachusetts

Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management